Trial Profile
A Phase I Study Assessing Single and Multiple Doses of AT-527 in Healthy and HCV-Infected Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Oct 2019
Price :
$35
*
At a glance
- Drugs Bemnifosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Proof of concept
- Sponsors Atea Pharmaceuticals
- 30 Sep 2019 Results published in the Antimicrobial Agents and Chemotherapy.
- 09 Nov 2018 Results presented in the Atea pharmaceuticals media release.
- 01 Oct 2018 Status changed from active, no longer recruiting to completed.